Pediatric underdosing of efavirenz: A pharmacokinetic study in Uganda

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 4, 2011, Pages 392-398

  Fillekes, Quirine ^a   Natukunda, Eva ^b   Balungi, Jackie ^c   Kendall, Lindsay ^d   Bwakura Dangarembizi, Mutsa ^e   Keishanyu, Rosette ^b   Ferrier, Alex ^d   Lutakome, Joseph ^f   Gibb, Diana M ^d   Burger, David M ^a   Walker, A Sarah ^d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^c Pediatric Infectious Diseases Centre   (Uganda)

^d MRC CLINICAL TRIALS UNIT   (United Kingdom)

^e UNIV OF ZIMBABWE MEDICAL SCHOOL   (Zimbabwe)

^f MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

children; efavirenz; HIV 1; pharmacokinetics; Uganda

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; EFAVIRENZ;

ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ERUPTION; DRUG UNDERDOSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; OPEN STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; UGANDA; UNSPECIFIED SIDE EFFECT;

ANTI-HIV AGENTS; BENZOXAZINES; CHILD; CHILD, PRESCHOOL; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; UGANDA;

EID: 80255137597     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318235e560     Document Type: Article

References (24)

1. World Health Organization. Antiretroviral Therapy of HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach-2010 Revision. Available at: http://www. who.int/hiv/pub/ guidelines/art/en/. Accessed October 3, 2010.
2. Sustiva [package insert]. New York, NY: Bristol-Myers Squibb; 2004.
3. Sharkey I, Boddy AV, Wallace H, et al. Body surface area estimation in children using weight alone: application in paediatric oncology. Br J Cancer. 2001;85:23-28. (Pubitemid 32695711)
4. Capparelli E, Rochon M, Robbins B, et al. IMPAACT P102 Study Team. Age-related pharmacokinetics of efavirenz solution. Abstract presented at: 16th Conference on Retroviruses and Opportunistic Infections; 2009; Montreal, Canada.
5. Hirt D, Urien S, Olivier M, et al. Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? Antimicrob Agents Chemother. 2009;53:4407-4413.
6. von Hentig N, Koenigs C, Elanjikal S, et al. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines. Eur J Med Res. 2006;11:377-380. (Pubitemid 44575697)
7. Ren Y, Nuttall JJ, Egbers C, et al. High prevalence of subtherapeutic plasma concentrations of efavirenz in children. J Acquir Immune Defic Syndr. 2007;45:133-136. (Pubitemid 46869804)
8. ter Heine R, Scherpbier HJ, Crommentuyn KM, et al. A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antivir Ther. 2008;13:779-787.
9. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253-1263. (Pubitemid 38496486)
10. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865-1873.
11. Musiime V, Kendall L, Bakeera-Kitaka S, et al. Pharmacokinetics and acceptability of once-versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. Antivir Ther. 2010;15:1115-1124.
12. Aarnoutse RE, Grintjes KJ, Telgt DS, et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and lowdose ritonavir in healthy volunteers. Clin Pharmacol Ther. 2002;71:57-67. (Pubitemid 34124039)
13. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med. 1998;17:407-429. (Pubitemid 28057006)
14. Saitoh A, Fletcher CV, Brundage R, et al. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr. 2007;45:280-285. (Pubitemid 47012374)
15. Puthanakit T, Tanpaiboon P, Aurpibul L, et al. Plasma efavirenz concentrations and the association with CYP2B6-516G .T polymorphism in HIV-infected Thai children. Antivir Ther. 2009;14:315-320.
16. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400. (Pubitemid 40065906)
17. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75. (Pubitemid 32055781)
18. World Health Organisation. Antiretroviral Therapy of HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach-2006. 2006.
19. Fletcher CV, Brundage RC, Fenton T, et al. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. Clin Pharmacol Ther. 2008;83:300-306.
20. Nyakutira C, Roshammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516G-,T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2008;64:357-365.
21. Klein K, Lang T, Saussele T, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics. 2005;15:861-873. (Pubitemid 41666768)
22. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001;11:399-415. (Pubitemid 32656581)
23. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400. (Pubitemid 40065906)
24. Leger P, Dillingham R, Beauharnais CA, et al. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J Infect Dis. 2009;200:955-964.